Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1Phase 1 1

Status

Completed 4

Sponsor Class

OTHER 33NIH 10INDUSTRY 4NETWORK 1

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 2CNS 2Head & Neck 1Breast 1

Conditions

Brain Neoplasms 2Lung Neoplasms 1Head and Neck Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

pembrolizumab 1023Carboplatin 964Paclitaxel 933Gemcitabine 794Cisplatin 751Docetaxel 683Bevacizumab 609Pemetrexed 502Nivolumab 487Cyclophosphamide 471Capecitabine 461Fluorouracil 418Dexamethasone 403Rituximab 372Oxaliplatin 348Injections 345atezolizumab 298Trastuzumab 298Leucovorin 288Cetuximab 282Irinotecan 268130-nm albumin-bound paclitaxel 254Prednisone 245Doxorubicin 240Ipilimumab 226Lenalidomide 220fludarabine 218Fulvestrant 217durvalumab 205Erlotinib Hydrochloride 188

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × alovudine × Clear all
NCT00453362 2017-03-31

A Study of Changes in FDG- and FLT-PET Imaging in Patients With Non-Small Cell Lung Cancer Following Treatment With Erlotinib

Genentech, Inc.

Phase 1/2 Completed
88 enrolled 18 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01480583 2016-07-13

GRABM-B

Angiochem Inc

Phase 2 Completed
85 enrolled
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT00847509 2013-09-27

FLT101

Siemens Molecular Imaging

Phase NA Completed
49 enrolled 4 charts
Head & NeckThoracic

Head and Neck Neoplasms, Lung Neoplasms

NCT00553748 2008-07-03

Phase I, Open Label, Single Center Safety Study of [F-18]FLT

Siemens Molecular Imaging

Phase 1 Completed
11 enrolled
CNS

Brain Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡